IceCure Medical Presents Promising Results from First-ever Interventional Radiology Study With Its Next Generation Liquid Nitrogen (LN2) Cryoablation System, ProSense™
Data presented at the European Association of Urology showed the ProSense™ system at 1-year follow-up was safe, effective and without serious adverse events for treating small kidney tumors
CAESAREA, Israel, March 20, 2019 /PRNewswire/ -- IceCure Medical, developer of the next generation liquid-nitrogen-based cryoablation technology to treat tumors by freezing, today announced promising results from its first-ever interventional radiology study.
Marking kidney cancer awareness month, the early evaluation, presented last week at the 34th Annual European Association of Urology Congress in Barcelona, reported the ProSense™ system was safe, effective and without serious adverse events in the treatment of small kidney tumors. Of 74 patients with 78 small kidney masses (≤ 4cm) treated, ProSense™ showed treatment success by lack of enhancement on CT or MRI in 93% (42 of 45) cases at 1 year follow-up.
"The ProSense™ system enables a safe, efficient and short minimal-invasive procedure that preserves renal function," said Prof. Ofer Nativ, Head of Bnei Zion Hospital Urology Department, Haifa, and principal investigator of the study. "There were over 400,000 new cases world-wide in 2018. The ProSense™ system adds a viable option to treat renal cancer in patients who have at least one comorbidity, had surgeries in the past or are a subject to multiple renal masses."
The minimally-invasive ProSense™ cryoablation system, uses next generation liquid nitrogen (LN2) technology, to enable the treatment of benign and cancerous tumors by freezing, without surgery.
"The ProSense™ system has already demonstrated excellent progress as a rapid, in-office solution for the treatment of breast tumors," said Eyal Shamir, CEO, IceCure Medical. "This new data adds to our growing clinical evidence for its expanding use in the field of interventional oncology as a non-surgical alternative to treat cancer of the kidney, lung, bone, and prostate."
The IceCure team will be providing a hands-on demonstration of the ProSense™ Cryoablation technology at the European Conference on Interventional Oncology (ECIO), April 8-11 in Amsterdam. To learn more or to schedule your personal demo, please visit icecure-medical.com or contact info@icecure-medical.com.
About IceCure Medical
Founded in 2006, Israel-based IceCure Medical (TASE: ICCM), develops and markets minimally-invasive cryoablation therapies for women's health and the interventional oncology market, with the primary focus areas being breast, kidney and lung cancer. The Company's proprietary, flagship ProSense™ liquid-nitrogen based system, has received US Food and Drug Administration (FDA) 510k and CE Mark approvals and is safe, innovative with clinical and economic benefits compared to the current standard of care.
View original content:SOURCE IceCure Medical
Company Codes: TelAviv:ICCM